Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea

Completed · Phase 2 · Has a placebo group

Conditions studied: Sleep Apnea, Obstructive

In brief

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Interestingly, the severity of OSA is profoundly reduced in deep sleep (called "slow wave sleep"), potentially via an increase in the stimulus required to arouse from sleep. Here the investigators test the idea that the medication called "tiagabine" improves slow wave sleep and reduces OSA severity. The investigators will also test whether tiagabine raises the arousal threshold (more negative esophageal pressure), and whether detailed OSA "phenotyping" characteristics can predict the improvement in OSA severity with this intervention.

Key facts

Study ID

NCT02387710

Run by

Brigham and Women's Hospital

People needed

18

Starts

2015-03-01

Expected to finish

2016-07-01

Last updated by the study team

2017-08-15

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed OSA (moderate-to-severe; apnea hypopnea index >15 events/hr)

You may not qualify if…

• History of seizures

Where it is running

• Sleep Disorders Research Program Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.